Bepharbel is a pharmaceutical CDMO specialized in liquid oral dosage forms. In parallel, the company has developed MMCR™, a proprietary liquid formulation platform technology enabling gastro‑resistant and prolonged release, and is now expanding this platform into veterinary development.
MMCR™ is a proprietary technology enabling gastro‑resistant and prolonged‑release properties in liquid formulations. Following human development, we aim to expand MMCR™ into companion animals and horses via co‑development and licensing.
Animal Health
Licensing Partner
Investment Partner
Distribution Partner
Research Collaboration
Commercialisation Partner
TRL 5: Technology validation in relevant environment